type 1 diabetes glp-1 receptor agonists are increasingly used to treat 2 and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1s and Type 1 Diabetes?

However, hypoglycemia is a potential side effect of GLP-1s if taken with insulin or sulfonylurea due to their glucose- lowering potential

This research illuminated ghrelins crucial role as an endogenous ligand for the GHS receptor, secreted primarily by the stomach, and its influence on GH release, food intake, and overall energy balance

Duriez, P., Ramoz, N., Gorwood, P., Viltart, O

This isn't because 1:1 is mechanistically optimal in some provable way it's because researchers studying combinations of these compounds chose 1:1 as the default and the literature accumulated around that choice

Diabetes medications need to be affordable because adherence is key